![]() | |
Clinical data | |
---|---|
ATC code |
|
Pharmacokinetic data | |
Elimination half-life | 13.7 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C26H32N2O5 |
Molar mass | 452.551 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Ensaculin (KA-672) is a drug from the coumarin family, which has been researched as a potential treatment for dementia. It acts on a number of receptor systems, being both a weak NMDA antagonist and a 5HT1A agonist.[1][2] Animal studies have shown promising nootropic effects,[3][4] although efficacy in humans has yet to be proven. It was well tolerated in human trials, with the main side effect being orthostatic hypotension (low blood pressure).[5]
| |
---|---|
AChE inhibitor medications |
|
Other medications |
|
Experimental BACE inhibitors |
|
Types of coumarins
| |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Aglycones |
| ||||||||||
glycosides |
| ||||||||||
derivatives |
| ||||||||||
Oligomers |
| ||||||||||
Synthetic |
|
![]() | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |